Diabetes Treatment Guideline Summary
Core Treatment Principles
For type 2 diabetes, metformin remains the foundation therapy combined with lifestyle modification, while patients with established cardiovascular disease, heart failure, or chronic kidney disease should receive SGLT2 inhibitors and/or GLP-1 receptor agonists with proven cardiovascular benefit regardless of A1C levels. 1, 2
Type 2 Diabetes Management Algorithm
Initial Therapy Selection
Step 1: Assess for High-Risk Comorbidities
If the patient has any of the following, medication selection is driven by organ protection, not just glucose control:
- Established atherosclerotic cardiovascular disease (ASCVD)
- Heart failure
- Chronic kidney disease
For these patients, initiate SGLT2 inhibitor and/or GLP-1 RA with demonstrated cardiovascular benefit alongside metformin 1, 2. This comorbidity-centric approach supersedes glucose-centric treatment.
Step 2: If No High-Risk Comorbidities Present
Start with metformin as foundation therapy 1, 3. Metformin has 60 years of clinical use demonstrating glucose-lowering efficacy, cardiovascular-renal benefits, and extremely low risk of lactic acidosis. Real-world evidence shows metformin discontinuation in advanced CKD (eGFR 15-30 mL/min/1.73m²) increases cardiovascular-renal events compared to continuation 3.
Lifestyle Modification (Non-Negotiable Foundation)
The 2026 AACE update emphasizes lifestyle modification and treatment of overweight/obesity as key pillars 2:
- Diet modification: Focus on nutrient-microbiota-metformin interactions through the gut-brain-kidney axis
- Exercise programs: Structured physical activity
- Weight management: Treat overweight/obesity aggressively as it directly impacts diabetes control
Treatment Intensification Based on A1C
When A1C is 1.5-2.0% Above Goal
Each oral agent added to metformin typically lowers A1C by 0.7-1.0% (8-11 mmol/mol). GLP-1 RAs or dual GIP/GLP-1 RA added to metformin usually achieve 1-2% A1C reduction 1.
Critical Rule: Do NOT combine GLP-1 RAs (or dual GIP/GLP-1 RA) with DPP-4 inhibitors—there is no added glucose-lowering benefit beyond GLP-1 RA alone 1.
When Greater Glucose Reduction is Needed
If not already on GLP-1 RA or dual GIP/GLP-1 RA, start these first before insulin—they may achieve A1C goals with lower hypoglycemia risk and favorable weight, cardiovascular, kidney, and liver profiles 1.
When to Initiate Insulin
Immediate insulin initiation if:
- A1C >10% (>86 mmol/mol) OR
- Blood glucose ≥300 mg/dL (≥16.7 mmol/L) OR
- Symptoms of hyperglycemia present OR
- Type 1 diabetes is a diagnostic possibility 1, 4
For T2DM with suboptimal control:
- Consider insulin when A1C ≥7.5% (≥58 mmol/mol) after optimizing oral agents
- Essential when A1C ≥10% (≥86 mmol/mol) despite optimal use of diet, physical activity, and other agents 4
Insulin Initiation and Titration
Starting Insulin in Type 2 Diabetes
Preferred method: Begin with long-acting basal insulin OR once-daily premixed insulin OR twice-daily premixed insulin, alone or combined with GLP-1 RA or other oral agents 4.
Initial basal insulin approach:
- Use fasting plasma glucose to titrate basal insulin
- If A1C goals not met, add rapid-acting or short-acting prandial insulin at mealtimes to control postprandial glucose spikes 4
For patients on GLP-1 RA + basal insulin: Consider fixed-ratio combination products (IDegLira or iGlarLixi) 1
Intensifying Insulin Regimens
Self-mixed/split insulin plan:
- 2/3 of total dose given before breakfast
- 1/3 given before dinner
- Add 4 units short/rapid-acting insulin to each injection OR 10% of reduced NPH dose
- Titrate each component individually 1
Progression to basal-bolus:
- Basal insulin + prandial insulin with each meal
- Use 4mm pen needles or 6mm syringe needles (shortest available)—they are safe, effective, less painful, and should be first-line choice
- Avoid intramuscular injections, especially with long-acting insulins, as severe hypoglycemia may result 4
Critical pitfall: Avoid lipohypertrophy by proper site rotation—injections into lipohypertrophic areas distort insulin absorption 4
Type 1 Diabetes Management
Insulin is the primary treatment for all T1DM patients 4.
Standard initiation: Multiple daily injections at diagnosis
- Short-acting or rapid-acting insulin analogue 0-15 minutes before meals
- One or more daily injections of intermediate or long-acting insulin
- Alternative: 2-3 premixed insulin injections per day 4
Target A1C: <7.5% (<58 mmol/mol) for all children with T1DM, including preschool children, aiming to minimize hyperglycemia, severe hypoglycemia, hypoglycemic unawareness, and reduce long-term complications 4
Monitoring: For patients with glycemic variability, combine A1C with self-monitoring of blood glucose results for best evaluation 4
Key Medication Combinations
Metformin + Insulin: This combination decreases weight gain, lowers insulin dose requirements, and reduces hypoglycemia compared to insulin alone 4. Do not abruptly discontinue oral medications when starting insulin—risk of rebound hyperglycemia 4.
Analogue vs Human Insulin: Analogue insulin is as effective as human insulin but associated with less postprandial hyperglycemia and delayed hypoglycemia 4.
Avoiding Therapeutic Inertia
Treatment intensification, deintensification, or modification should not be delayed for patients not meeting individualized goals 1. The incorporation of high-glycemic-efficacy therapies (GLP-1 RAs, dual GIP/GLP-1 RA, SGLT2 inhibitors) may reduce need for agents that increase hypoglycemia risk and weight gain.
Practical Considerations
Blood glucose monitoring: Integral to effective insulin therapy—cannot be omitted. Use FPG to titrate basal insulin; use both FPG and PPG to titrate mealtime insulin 4.
Needle reuse: Not recommended by manufacturers and associated with lipohypertrophy. However, patients who reuse needles should not be subjected to alarming claims of excessive morbidity 4.
Gastrointestinal side effects of metformin: Understanding metformin-food-microbiota interactions helps optimize use and mitigate side effects including vitamin B12 deficiency 3.